

1 **The quantitative landscape of the neutralizing antibody response to SARS-CoV-2**

2

3

4 Pranesh Padmanabhan^{1,*}, Rajat Desikan^{2,‡}, Narendra M. Dixit^{2,3,*}

5

6 ¹Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of
7 Queensland, Brisbane, Australia 4072

8 ²Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012

9 ³Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India 560012

10 [‡]Current Address: Certara QSP, Certara UK Limited, Sheffield, UK

11

12

13 *Correspondence:

14 Pranesh Padmanabhan, Narendra M. Dixit

15 Email: p.padmanabhan@uq.edu.au; narendra@iisc.ac.in

16

17

18 Manuscript details:

19 Abstract: 150 words; Text: ~3300 words; Figures: 6; References: 51

20 Supplementary Materials: Tables: 1; Figures: 9; References: 20


21 **Abstract**

22 Neutralizing antibodies (NAbs) appear promising interventions against SARS-CoV-2
23 infection. Over 100 NAbs have been identified so far and several are in clinical trials. Yet,
24 which NAbs would be the most potent remains unclear. Here, we analysed reported *in vitro*
25 dose-response curves (DRCs) of >70 NAbs and estimated corresponding 50% inhibitory
26 concentrations, slope parameters, and instantaneous inhibitory potentials (*IIPs*), presenting a
27 comprehensive quantitative landscape of NAb responses to SARS-CoV-2. NAbs with high
28 *IIPs* are likely to be potent. To assess the applicability of the landscape *in vivo*, we analysed
29 available DRCs of NAbs from individual patients and found that the responses closely
30 resembled the landscape. Further, we created virtual patient plasma samples by randomly
31 sampling NAbs from the landscape and found that they recapitulated plasma dilution assays
32 from convalescent patients. The landscape thus offers a facile tool for benchmarking NAbs
33 and would aid the development of NAb-based therapies for SARS-CoV-2 infection.

34 **Introduction**

35 The pace of the development of neutralizing antibodies (NAbs) against the severe acute
36 respiratory syndrome coronavirus 2 (SARS-CoV-2) has been phenomenal¹. Over 100
37 monoclonal NAbs have been identified so far and several of them, namely, LY-CoV555,
38 JS016, REGN10933/10987, VIR-7831/7832, TY027, SCTA01, BRII-196/198, CT-P59,
39 AZD8895/1061 and MW33 are already in clinical trials^{2,3}. Drugs and vaccines specifically
40 targeting SARS-CoV-2 are not yet available. Plasma therapy, where plasma isolated from
41 convalescent patients is injected into infected individuals, has shown some success and is in
42 use in some countries to treat severe SARS-CoV-2 infection⁴⁻⁶. The reported NAbs have been
43 isolated from convalescent patients and subsequently selected or engineered for improved
44 potency^{1,2}, and are therefore expected to work better than plasma therapy⁷. NAbs thus hold
45 promise of evolving into a powerful weapon against SARS-CoV-2 infection. Passive
46 immunization with antibodies has shown promise in several other settings, including HIV-1
47 infection^{8,9}, autoimmune disorders^{10,11}, and cancers^{12,13}. With the large and rapidly growing
48 SARS-CoV-2 NAb repertoire, a question that arises is which of these NAbs should be taken
49 up for clinical development. A comparative evaluation of the NAbs has not been performed.

50 Studies identifying NAbs typically report the 50% inhibitory concentration, IC_{50} , of the
51 NAbs, the concentration at which viral infectivity is reduced by 50% of that in the absence of
52 the NAbs (Fig. 1A). The inference drawn is that the lower is the IC_{50} , the more potent is the
53 NAb (Fig. 1A). A limitation of this approach arises from the non-linear dependence of the
54 neutralization efficacy of NAbs on their concentrations because of which a NAb with a lower



55

56 **Figure 1. Illustration of assays and metrics characterizing NAb.** (A, B) The fraction of
 57 infection events unaffected by NAb, f_u , with the same m and different values of IC_{50} (A) and
 58 with different values of m and IC_{50} (B). In A and B, horizontal lines mark $f_u = 50\%$. In B,
 59 vertical line marks NAb concentration, D , of $100 \mu\text{g/ml}$. (C) IIP computed at $100 \mu\text{g/ml}$ for
 60 NAb with the same IC_{50} but different values of m .

61

62 IC_{50} may be much less efficacious than a NAb with a higher IC_{50} when the two are used at
 63 physiologically relevant concentrations, which are typically much larger than IC_{50} (Fig. 1B).

64 This problem was first recognized with antiretroviral drugs¹⁴⁻¹⁷. It was overcome by the

65 construction and use of a metric called the instantaneous inhibitory potential, denoted IIP ,

66 which is a composite of the IC_{50} and the slope of the dose-response curve (DRC), m , the latter

67 a measure of the extent of the non-linearity in the dependence of the efficacy on the

68 concentration. $IIP = \log_{10} \left(1 + \left(\frac{D}{IC_{50}} \right)^m \right)$ is the log decline of viremia in a single round

69 infection assay due to the drug at concentration D . Thus, when two drugs are used at the same


70 concentration, the one with the higher IIP would be more efficacious (Fig. 1C). Drug

71 combinations with higher IIP values have been shown to have better efficacies, with HIV-

72 $1^{14,15}$ and hepatitis C virus (HCV)^{18,19}. *IIP* has since been extended to antibodies and shown to
 73 predict the relative efficacies of HIV-1 and HCV antibodies^{18,20}.

74

75



76

77 **Figure 2. Schematic of the workflow to chart out the quantitative landscape of SARS-**
 78 **CoV-2 NABs.** We collated data from all studies that reported DRCs of NABs using SARS-
 79 CoV-2 pseudotyped virions. The assays estimate the fraction of infection events
 80 affected/unaffected by the NABs as a function of the NAb concentration. We extracted and
 81 analysed the data using both the standard DRC equation (Eq. [1]) and the median-effect

82 equation (Eq. [2]) to estimate IC_{50} and m . We then computed $IIP_{100} = \log_{10} \left(1 + \left(\frac{100}{IC_{50}} \right)^m \right)$

83 using the estimates obtained by both equations. NABs with consistent estimates were
 84 considered for rank-ordering.

85

86 Here, we decided to examine whether the *IIP* could be applied to comparatively
 87 evaluate SARS-CoV-2 NABs. Unlike IC_{50} values, which are routinely reported, the values of

88 m have rarely been reported for SARS-CoV-2 NABs, precluding the estimation of IIP for
89 most NABs. We therefore collated all the available *in vitro* DRCs of SARS-CoV-2 NABs and
90 analysed them to estimate both IC_{50} and m , and then IIP (Fig. 2). A comprehensive landscape
91 of NAb responses to SARS-CoV-2 emerged. We tested the applicability of the landscape *in*
92 *vivo* by examining the spectrum of responses in individual patients and by constructing
93 virtual patient plasma samples to recapitulate plasma dilution assays.

94

95 **Results**

96 *Analysis of DRCs and the variability in IC_{50} and m*

97 We collated and analysed the reported DRCs of over 70 NABs obtained using SARS-CoV-2
98 pseudotyped virus infection assays (Figs. 2 and 3; Methods; Table S1)²¹⁻³⁹. These NABs have
99 been proposed as the most promising from among many examined in the respective studies.
100 A vast majority of the DRCs could be fit well with the median effect equation (Fig. 3A; Fig.
101 S1) as well as the standard dose-response equation (Fig. 3B; Fig. S2), with the two yielding
102 very similar estimates of the fit parameters IC_{50} and m (Table S1). The resulting estimates of
103 IC_{50} were in close agreement with the reported estimates, giving us confidence in the fits
104 (Fig. S3A; Table S1). The IC_{50} displayed a wide variation across NABs, ranging from $\sim 10^{-3}$
105 $\mu\text{g/ml}$ to $\sim 140 \mu\text{g/ml}$ (Fig. 3C). m too displayed wide variability, spanning the range ~ 0.2 to
106 2.3 (Fig. 3D). As mentioned above, values of m have not been reported in previous studies.
107 We examined whether the variability in IC_{50} and m was restricted to a particular pseudotyped
108 virus construct or backbone used (Fig. 3F, 3G), the cell line used (Fig. 3H, 3I), or assay
109 conditions, which could vary across studies (Fig. S3B, S3C), and found that not to be true.




Figure 3. Estimates of IC_{50} and m of SARS-CoV-2 NABs. (A, B) Fits (lines) of the median-effect equation (A) and the standard dose-response curve equation (B) to published experimental data (circles). The unit of IC_{50} is $\mu\text{g/ml}$. Experimental data points with $1\% < f_u < 99\%$ (filled circles) were considered for parameter estimation. (C, D) The best-fit estimates of IC_{50} (C) and m (D). (E-H) The variability in IC_{50} and m within different pseudotyped virus constructs or backbones (E, F) and cell lines (G, H). In G and H, 293, 293T, HeLa and A549 cells expressing ACE2 were used in the reported experiments.

The variation was thus intrinsic to the NABs. Furthermore, akin to HIV-1 antibodies²⁰, the variations in IC_{50} and m of the SARS-CoV-2 NABs appeared independent. For instance, the NABs BD-361 and REGN10954 had similar IC_{50} (both $\sim 0.04 \mu\text{g/ml}$), but vastly different m (~ 0.7 and ~ 1.5 , respectively), whereas the NABs CC12.3 and 515-5 had vastly different IC_{50} ($\sim 0.02 \mu\text{g/ml}$ and $1.6 \mu\text{g/ml}$, respectively), but similar m (both ~ 1). This independent variability of IC_{50} and m implied that IC_{50} alone was an inadequate metric to characterize the NABs. Indeed, at concentrations of $10 \times IC_{50}$, REGN10954 would have an efficacy of ~ 0.97

and therefore perform better than BD-361, which would have an efficacy ~ 0.84 , despite the two having similar values of the IC_{50} .




Figure 4. The SARS-CoV-2 NAb landscape. (A) IC_{50} and m for SARS-CoV-2 NAb (circles colour-coded with the respective IIP values computed at 100 $\mu\text{g/ml}$). Each symbol represents one NAb. 8 NAb that have multiple neutralisation curves reported are represented multiple times (Table S1). Lines are loci of points corresponding to fixed IIP values computed at 100 $\mu\text{g/ml}$. (B) The distribution of IIP_{100} values of NAb. Average IIP_{100} values are used for the 8 NAb mentioned above.

IIP estimates, the NAb landscape, and benchmarks

Following previous studies on HIV-1 and HCV¹⁸⁻²⁰, we therefore computed next the IIP values of the NAb at $D=100$ $\mu\text{g/ml}$. We found that the IIP displayed a wide range, from ~ 0.3 to 7.2 (Figs. 4 and 5), giving a glimpse of the range of NAb efficacies realizable *in vivo*. (IIP values at $D = 50$ $\mu\text{g/ml}$ displayed negligible deviations in the rank-ordering of the NAb; Fig. S4). NAb with high IIP s were those with low IC_{50} and high m (Fig. 4A). Contour lines of constant IIP on an IC_{50} - m plot helped visualize the dependence of the IIP on IC_{50} and m


(Fig. 4A). We found that 5 NABs had $IIP > 5$. These, from our calculations, would be the most promising NABs. (Similar predictions have been made with broadly neutralizing antibodies of HIV-1²⁰.) The numbers increased for smaller IIP , with 9 NABs between 4 and 5, 10 between 3 and 4, and so on (Fig. 4B). The highest number, 22, had modest IIP s, between 1 and 2. A much smaller number, 9, had IIP s between 0 and 1, which was predictive of poor *in vivo* efficacy.

This distribution of IIP values demonstrates the wide spectrum of neutralization efficiencies of NABs that have all been deemed promising in different studies. The threshold IIP for clinical success is not known. While many NABs with low IIP s may thus prove successful, it may be advantageous to choose those with high IIP s for they are likely to succeed with smaller dosages and/or fewer doses than those with low IIP s. Based on the resources available, thus, the top few NABs, *i.e.*, those with the highest IIP values (Fig. 5), could be considered for further development. We note that the top NABs would have been different had the IC_{50} or m alone been used to characterize the NABs, reiterating the inadequacy of these metrics individually in characterizing NABs. (Figs. S5 and S6). The range of IIP s we estimated also sets benchmarks for NABs that may be discovered/engineered in the future. They are unlikely to be competitive if they have $IIP < 5$ and more certainly so with $IIP < 4$.

NAb responses in patients


An important question in choosing NABs based on our analysis above is the applicability of the landscape to *in vivo* settings. The applicability of *in vitro* estimates to *in*

166 *vivo* settings may not be quantitative, although proportionality has been suggested⁴⁰. To test
167 this here, we



168

169 **Figure 5. Comparison of SARS-CoV-2 NAbS based on IIP.** A rank-order of SARS-CoV-2
170 NAbS based on IIP computed at 100 $\mu\text{g/ml}$. Average IIP is reported for 8 NAbS that have
171 multiple neutralisation curves (Table S1).



172

173 **Figure 6. Applicability of the NAb landscape *in vivo*.** (A, B) The variability in IC_{50} and m
174 of different NAbS from eight patients (see Fig S8). The m values of NAbS with $\text{IC}_{50} \geq 1 \mu\text{g/ml}$
175 could not be estimated and these NAbS are not shown. (C) IC_{50} and m for SARS-CoV-2
176 NAbS isolated from patients (circles colour-coded with the respective IIP values computed at
177 100 $\mu\text{g/ml}$). Each symbol represents one NAb. Contour lines represent loci of constant IIP.
178 (D) Predictions (grey lines) of the fraction of infection events unaffected by NAbS, f_u , in the
179 presence of increasing concentrations of plasma derived from virtual patients. We assumed
180 ten NAbS per patient. IC_{50} for each NAb was sampled from the range 0.001 and 100 $\mu\text{g/ml}$
181 and m from the range 0.2 and 2. Blues lines are fits to published data from three
182 representative patients (see Fig. S8). *Inset*: half-maximal inhibitory plasma neutralizing titre,
183 NT_{50} , values corresponding to the dilution curves in D. (E-H) Predictions of dilution curves of
184 hypothetical patient plasma samples. (E, F) Average IC_{50} (E) and m (F) of groups A and B.
185 (G, H) Comparison of NT_{50} (G) and IIP (H) between groups A and B. In D-H, $D_0 = 100$
186 $\mu\text{g/ml}$.

187

188 examined the spectrum of NAb responses reported within individual patients and compared
189 them with the landscape. We considered reported DRCs of different NAbS from eight

190 patients²⁴ and estimated the corresponding IC_{50} and m (Figs. 6A, 6B, S7). We found the
191 ranges of IC_{50} and m within each patient to be similar to the ranges in our landscape. For
192 instance, in the patient COV021²⁴, the IC_{50} range was $\sim 5 \times 10^{-3}$ to >1 $\mu\text{g/ml}$ and the m values
193 were in the range ~ 0.65 to 1.8 . (Inhibition assays were not performed at NAb concentrations
194 above 1 $\mu\text{g/ml}$, precluding analysis of NAb with $IC_{50} > 1$ $\mu\text{g/ml}$, of which there were
195 several²⁴. Such NAb, expected to have low IIP values, are therefore missing in our
196 landscape.) Similarly, in patient COV047, the IC_{50} range was $\sim 3 \times 10^{-3}$ to >1 $\mu\text{g/ml}$ and the m
197 values were in the range ~ 0.6 to 1.5 . In comparison, recall that the corresponding ranges were
198 $\sim 10^{-3}$ to 140 $\mu\text{g/ml}$ and ~ 0.2 to 2.3 in the NAb landscape (Figs. 3, 4). We next computed $IIPs$
199 of all of these NAb and found them to lie in the range of 1 to 8 , again in consonance with the
200 landscape (Figs. 6C, 4A). These comparisons suggest that our landscape was representative
201 of the spectrum of NAb responses within individuals.

202 To test this further, we performed *in silico* simulations that mimic plasma dilution
203 assays used to quantify the antiviral efficacy of convalescent patient plasma samples (Fig.
204 6D). We assumed that the plasma samples contained 10 different NAb with each NAb
205 defined by its IC_{50} and m . We created *in silico* virtual patient plasma samples by randomly
206 selecting IC_{50} and m for each of the 10 NAb from the ranges identified from our landscape
207 (Fig. 4). We assumed Loewe additivity⁴¹⁻⁴³ between the different NAb to describe their
208 overall efficacy. We found that with these *in silico* samples, we were able to closely
209 recapitulate experimental serial dilution assays (Figs. 6D, S8), giving us confidence in the
210 NAb landscape. The values of NT_{50} , the dilution at which neutralization efficiency decreases

211 by 50% of the undiluted plasma, we estimated (Fig. 5D inset) were also comparable to the
212 values estimated from patient samples ($\sim 10^1$ to 10^4 ; see Ref. 24).

213 These comparisons also re-emphasize the need to choose NABs or convalescent patient
214 plasma for treatment based not only on the IC_{50} but also m . To elucidate this further, we
215 repeated our *in silico* analysis by comparing simulated samples containing NABs with similar
216 IC_{50} values but low (group A) or high (group B) m (Fig. 6E, 6F). Although simulated plasma
217 samples from groups A and B had similar NT_{50} (Fig. 6G), samples with high m on average
218 had much higher values of IIP_{100} than those with low m (Fig. 6H). Thus, in interpreting
219 plasma dilution assays and in designing plasma and NAb therapies, accounting for m , which
220 has been ignored thus far, would be as important as IC_{50} .

222 Discussion

223 Our study presents the first quantitative landscape of the NAb responses to SARS-
224 COV-2. We deduced the landscape by the analysis of reported data from over 70 NABs,
225 which we collated into an extensive and mineable compendium. Importantly, the landscape
226 recapitulated the spectrum of NAb responses seen in convalescent patients. We also rank-
227 ordered the NABs based on their $IIPs$, identifying promising candidates for further
228 development, and setting benchmarks for NABs that may be identified in the future.

229 An intriguing question that emerges is the nature of the NABs that display high IIP
230 values. Correlations have been proposed between the binding affinity of antibodies for their
231 targets and the resulting neutralization efficiency, typically $IC_{50}^{44,45}$. The origins of m are
232 much less explored. Cooperative effects have been argued to lead to high m^{46} . With SARS-

233 CoV-2, these effects are yet to be elucidated. In many cases, the targets and/or the mechanism
234 of action of the NAbS are not known. For instance, the potent NAb 47D11 targeting the spike
235 protein S of SARS-CoV-2 blocks virus entry without preventing the binding between S and
236 the host receptor ACE-2 required for entry³². As future studies establish molecular details of
237 the SARS-CoV-2 entry process^{37,47}, identifying unifying characteristics of the NAbS with
238 high *IIP* values would become feasible, allowing rational design of even more potent NAbS.

239 Our analysis used data from pseudovirus assays because of the ease of interpretation of
240 the assays and the known correlation of the *IIP* thus estimated with *in vivo* efficacy⁴⁸.
241 Analysis of assays using authentic SARS-CoV-2 virus, which would establish our findings on
242 firmer footing, are not forthcoming. *m* is difficult to estimate using data from multi-round
243 infection assays⁴⁹. Further, viral kinetic parameters introduce confounding effects that are not
244 readily delineated^{49,50}, posing challenges that extend beyond SARS-CoV-2. Nonetheless, the
245 ability of our NAb landscape to recapitulate patient NAb responses and plasma dilution
246 assays suggests that our findings are likely to be consistent with the scenario *in vivo*. Our aim
247 is not to offer accurate estimates of the *in vivo* potency of NAbS. Rather, it is to present a
248 systematic way of comparatively evaluating NAbS for further development and a benchmark
249 for new NAbS.

250 In summary, our study collates, compares, and ranks available NAbS, laying out the
251 landscape of NAb responses currently observed including in patients, and informs ongoing
252 efforts to develop NAb-based interventions for SARS-CoV-2 infection.

254 **Methods**

255 **Data**

256 We considered data from studies that reported dose-response curves of NAb using
257 SARS-CoV-2 pseudotyped virions²¹⁻³⁹. The assays estimate the fraction of infection events
258 unaffected by the NAb as a function of the NAb concentration (Fig. 2). Data from such
259 assays have been successfully used to evaluate m and IC_{50} of antibodies against HIV-1²⁰ and
260 HCV¹⁸. We extracted the data using Engauge Digitizer 12.1 and ensured consistency
261 wherever possible with reported details, such as dilution levels used.

262

263 **Analysis of DRCs**

264 We used both the standard dose-response curve equation (Eq. [1]) and the median-
265 effect equation (Eq. [2]) to analyse the data.

$$266 \quad f_u = 1 - f_a = \frac{(IC_{50})^m}{(D)^m + (IC_{50})^m} \quad (1)$$

$$267 \quad \log_{10} \left(\frac{f_a}{f_u} \right) = m \log_{10} \left(\frac{D}{IC_{50}} \right) \quad (2)$$

268 Here, f_u and f_a are the fraction of infection events unaffected and affected by the
269 NAb in a single round of infection, D is the NAb concentration, IC_{50} is the half-maximal
270 inhibitory concentration and m is the slope. Data was fitted using the tool NLINFIT in
271 MATLAB R2017b. Data points with $1\% < f_u < 99\%$ were considered for parameter
272 estimation. We fit the data using Eq. [1] and Eq. [2] separately and obtained estimates of IC_{50}
273 and m for each NAb as well as associated 95% confidence intervals. We then computed

274 $IIP_{100} = \log_{10} \left(1 + \left(\frac{100}{IC_{50}} \right)^m \right)$ using the estimates obtained using Eq. [1] and Eq. [2]. In most
275 cases, the IIP_{100} values were close to each other. We did not include NAbS for which IIP_{100}
276 values estimated using the two methods deviated by 20% or more in our analysis, for the
277 deviation indicated that such NAbS either did not conform to the trends expected by Eqs. [1]
278 and [2] or had large uncertainties in the data precluding robust parameter estimation. We also
279 repeated our analysis with a more liberal threshold of 30% deviation for acceptance (Fig. S9).
280 The details of the NAbS and parameter estimates are presented in Table S1.

281

282 *In silico simulation of plasma dilution assays*

283 We simulated plasma dilution experiments as follows. We assumed that the plasma
284 contained N NAbS with equimolar concentrations. For each NAb, IC_{50} was sampled from the
285 range 0.001 $\mu\text{g/ml}$ to 100 $\mu\text{g/ml}$ (Fig. 3C) and m was sampled from the range 0.2 to 2 (Fig.
286 3D). This range was consistent with the range seen from the spectrum of NAbS within
287 individual patients (Fig. 6A). The reciprocal plasma dilution curve was predicted assuming
288 Loewe additivity between the different NAbS^{41,42} using

$$289 \sum_{i=1}^N \frac{D_i / \gamma}{IC_{50_i} \left(\frac{1}{\varepsilon} - 1 \right)^{-1/m_i}} = 1 \quad (3)$$

290 Here, γ is the plasma dilution factor. ε is the fraction of infection events affected by
291 the plasma in a single round of infection. D_i is the concentration of the i^{th} NAb in the plasma
292 before dilution, IC_{50_i} is its half-maximal inhibitory concentration and m_i its slope, with

293 $i \in \{1, 2, \dots, N\}$. We assumed $N = 10$ in our simulations, based on the number of NABs with
294 significant neutralization efficacy seen in patients²⁵. We estimated the value of γ at which
295 $\varepsilon = 0.5$ as the corresponding NT_{50} . We chose D_i as D_0 / N , and set $D_0 = 100 \mu\text{g/ml}$.

296 We repeated these simulations 100 times, with each simulation representative of an
297 individual patient. We compared the resulting predictions with observations from 3
298 patients⁵¹, which also we digitized (Fig. S8). The equation $f_u = \frac{(\gamma)^m}{(\gamma)^m + (NT_{50})^m}$ was fit to the
299 observations from 3 patients. Here, m is the slope parameter, γ is the plasma dilution and NT_{50}
300 is the half-maximal inhibitory plasma neutralizing titre. We also performed simulations where
301 the IC_{50} values were kept similar between pairs of realizations, but m values were chosen
302 from non-overlapping ranges. Using these simulations, we predicted how the expected
303 plasma dilution assay data and the corresponding IIP values would vary with m .

304

305 **Acknowledgements**

306 This work was supported by the DBT/Wellcome Trust India Alliance Senior
307 Fellowship IA/S/14/1/501307 to NMD.

308

309 **Conflicting interests**

310 The authors declare that no conflicts of interests exist.

311

312 **References**

- 313 1. Kelley, B. Developing therapeutic monoclonal antibodies at pandemic pace. *Nat*
314 *Biotechnol* **38**, 540-545 (2020).
- 315 2. Renn, A., Fu, Y., Hu, X., Hall, M.D. & Simeonov, A. Fruitful Neutralizing Antibody
316 Pipeline Brings Hope To Defeat SARS-Cov-2. *Trends Pharmacol Sci* (2020).
- 317 3. Yang, L., *et al.* COVID-19 antibody therapeutics tracker: a global online database of
318 antibody therapeutics for the prevention and treatment of COVID-19. *Antibody*
319 *Therapeutics* **3**, 204-211 (2020).
- 320 4. Focosi, D., Anderson, A.O., Tang, J.W. & Tuccori, M. Convalescent Plasma Therapy
321 for COVID-19: State of the Art. *Clin Microbiol Rev* **33**, e00072-00020 (2020).
- 322 5. Chen, L., Xiong, J., Bao, L. & Shi, Y. Convalescent plasma as a potential therapy for
323 COVID-19. *Lancet Infect Dis* **20**, 398-400 (2020).
- 324 6. Duan, K., *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19
325 patients. *Proc Natl Acad Sci U S A* **117**, 9490-9496 (2020).
- 326 7. Abraham, J. Passive antibody therapy in COVID-19. *Nat Rev Immunol* **20**, 401-403
327 (2020).
- 328 8. Walker, L.M. & Burton, D.R. Passive immunotherapy of viral infections: 'super-
329 antibodies' enter the fray. *Nat Rev Immunol* **18**, 297-308 (2018).
- 330 9. Caskey, M., Klein, F. & Nussenzweig, M.C. Broadly neutralizing anti-HIV-1
331 monoclonal antibodies in the clinic. *Nat Med* **25**, 547-553 (2019).
- 332 10. Beck, A., Wurch, T., Bailly, C. & Corvaia, N. Strategies and challenges for the next
333 generation of therapeutic antibodies. *Nat Rev Immunol* **10**, 345-352 (2010).
- 334 11. Chan, A.C. & Carter, P.J. Therapeutic antibodies for autoimmunity and inflammation.
335 *Nat Rev Immunol* **10**, 301-316 (2010).
- 336 12. Scott, A.M., Wolchok, J.D. & Old, L.J. Antibody therapy of cancer. *Nat Rev Cancer*
337 **12**, 278-287 (2012).
- 338 13. Sliwkowski, M.X. & Mellman, I. Antibody therapeutics in cancer. *Science* **341**, 1192-
339 1198 (2013).
- 340 14. Shen, L., *et al.* Dose-response curve slope sets class-specific limits on inhibitory
341 potential of anti-HIV drugs. *Nat Med* **14**, 762-766 (2008).
- 342 15. Jilek, B.L., *et al.* A quantitative basis for antiretroviral therapy for HIV-1 infection. *Nat*
343 *Med* **18**, 446-451 (2012).

- 344 16. Sampah, M.E., Shen, L., Jilek, B.L. & Siliciano, R.F. Dose-response curve slope is a
345 missing dimension in the analysis of HIV-1 drug resistance. *Proc Natl Acad Sci U S A*
346 **108**, 7613-7618 (2011).
- 347 17. Laskey, S.B. & Siliciano, R.F. Quantitative evaluation of the antiretroviral efficacy of
348 dolutegravir. *JCI Insight* **1**, e90033 (2016).
- 349 18. Padmanabhan, P. & Dixit, N.M. Inhibitors of hepatitis C virus entry may be potent
350 ingredients of optimal drug combinations. *Proc Natl Acad Sci U S A* **114**, E4524-
351 E4526 (2017).
- 352 19. Koizumi, Y., *et al.* Quantifying antiviral activity optimizes drug combinations against
353 hepatitis C virus infection. *Proc Natl Acad Sci U S A* **114**, 1922-1927 (2017).
- 354 20. Webb, N.E., Montefiori, D.C. & Lee, B. Dose-response curve slope helps predict
355 therapeutic potency and breadth of HIV broadly neutralizing antibodies. *Nat Commun*
356 **6**, 8443 (2015).
- 357 21. Seydoux, E., *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals
358 Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
359 *Immunity* **53**, 98-105 e105 (2020).
- 360 22. Zost, S.J., *et al.* Potently neutralizing and protective human antibodies against SARS-
361 CoV-2. *Nature* **584**, 443-449 (2020).
- 362 23. Wan, J., *et al.* Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-
363 CoV-2 Infection. *Cell Rep* **32**, 107918 (2020).
- 364 24. Robbiani, D.F., *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent
365 individuals. *Nature* **584**, 437-442 (2020).
- 366 25. Liu, L., *et al.* Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2
367 spike. *Nature* **584**, 450-456 (2020).
- 368 26. Chi, X., *et al.* A neutralizing human antibody binds to the N-terminal domain of the
369 Spike protein of SARS-CoV-2. *Science* **369**, 650-655 (2020).
- 370 27. Hansen, J., *et al.* Studies in humanized mice and convalescent humans yield a SARS-
371 CoV-2 antibody cocktail. *Science* **369**, 1010-1014 (2020).
- 372 28. Ju, B., *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*
373 **584**, 115-119 (2020).
- 374 29. Lei, C., *et al.* Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant
375 ACE2-Ig. *Nat Commun* **11**, 2070 (2020).

- 376 30. Shi, R., *et al.* A human neutralizing antibody targets the receptor-binding site of
377 SARS-CoV-2. *Nature* **584**, 120-124 (2020).
- 378 31. Cao, Y., *et al.* Potent Neutralizing Antibodies against SARS-CoV-2 Identified by
379 High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **182**,
380 73-84 e16 (2020).
- 381 32. Wang, C., *et al.* A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat*
382 *Commun* **11**, 2251 (2020).
- 383 33. Chen, X., *et al.* Human monoclonal antibodies block the binding of SARS-CoV-2
384 spike protein to angiotensin converting enzyme 2 receptor. *Cell Mol Immunol* **17**, 647-
385 649 (2020).
- 386 34. Lv, Z., *et al.* Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a
387 potent therapeutic antibody. *Science* **369**, 1505-1509 (2020).
- 388 35. Rogers, T.F., *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies and
389 protection from disease in a small animal model. *Science* **369**, 956-963 (2020).
- 390 36. Wec, A.Z., *et al.* Broad neutralization of SARS-related viruses by human monoclonal
391 antibodies. *Science* **369**, 731-736 (2020).
- 392 37. Barnes, C.O., *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike
393 Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842
394 e816 (2020).
- 395 38. Pinto, D., *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-
396 CoV antibody. *Nature* **583**, 290-295 (2020).
- 397 39. Hanke, L., *et al.* An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor
398 interaction. *Nat Commun* **11**, 4420 (2020).
- 399 40. van Gils, M.J. & Sanders, R.W. In vivo protection by broadly neutralizing HIV
400 antibodies. *Trends Microbiol* **22**, 550-551 (2014).
- 401 41. Padmanabhan, P. & Dixit, N.M. Modeling Suggests a Mechanism of Synergy Between
402 Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes. *CPT Pharmacometrics*
403 *Syst Pharmacol* **4**, 445-453 (2015).
- 404 42. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of
405 synergism and antagonism in drug combination studies. *Pharmacol Rev* **58**, 621-681
406 (2006).
- 407 43. Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological
408 landscape. *Pharmacol Res Perspect* **3**, e00149 (2015).

- 409 44. Liao, H.X., *et al.* Co-evolution of a broadly neutralizing HIV-1 antibody and founder
410 virus. *Nature* **496**, 469-476 (2013).
- 411 45. Bonsignori, M., *et al.* Maturation Pathway from Germline to Broad HIV-1 Neutralizer
412 of a CD4-Mimic Antibody. *Cell* **165**, 449-463 (2016).
- 413 46. Shen, L., *et al.* A critical subset model provides a conceptual basis for the high
414 antiviral activity of major HIV drugs. *Sci Transl Med* **3**, 91ra63 (2011).
- 415 47. Wang, Y., Liu, M. & Gao, J. Enhanced receptor binding of SARS-CoV-2 through
416 networks of hydrogen-bonding and hydrophobic interactions. *Proc Natl Acad Sci U S*
417 *A* **117**, 13967-13974 (2020).
- 418 48. Rosenbloom, D.I., Hill, A.L., Rabi, S.A., Siliciano, R.F. & Nowak, M.A. Antiretroviral
419 dynamics determines HIV evolution and predicts therapy outcome. *Nat Med* **18**, 1378-
420 1385 (2012).
- 421 49. Ferguson, N.M., Fraser, C. & Anderson, R.M. Viral dynamics and anti-viral
422 pharmacodynamics: rethinking in vitro measures of drug potency. *Trends Pharmacol*
423 *Sci* **22**, 97-100 (2001).
- 424 50. Padmanabhan, P. & Dixit, N.M. Mathematical model of viral kinetics in vitro estimates
425 the number of E2-CD81 complexes necessary for hepatitis C virus entry. *PLoS Comput*
426 *Biol* **7**, e1002307 (2011).
- 427 51. Brouwer, P.J.M., *et al.* Potent neutralizing antibodies from COVID-19 patients define
428 multiple targets of vulnerability. *Science* **369**, 643-650 (2020).
- 429